Switch to:
Also traded in: Austria, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.75
BIIB's Cash-to-Debt is ranked lower than
87% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. BIIB: 0.75 )
Ranked among companies with meaningful Cash-to-Debt only.
BIIB' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.25  Med: 2.39 Max: No Debt
Current: 0.75
0.25
No Debt
Equity-to-Asset 0.54
BIIB's Equity-to-Asset is ranked lower than
70% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. BIIB: 0.54 )
Ranked among companies with meaningful Equity-to-Asset only.
BIIB' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.76 Max: 0.96
Current: 0.54
0.48
0.96
Debt-to-Equity 0.43
BIIB's Debt-to-Equity is ranked lower than
65% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. BIIB: 0.43 )
Ranked among companies with meaningful Debt-to-Equity only.
BIIB' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01  Med: 0.13 Max: 0.78
Current: 0.43
0.01
0.78
Debt-to-EBITDA 0.85
BIIB's Debt-to-EBITDA is ranked higher than
68% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. BIIB: 0.85 )
Ranked among companies with meaningful Debt-to-EBITDA only.
BIIB' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.13  Med: 0.64 Max: 1.2
Current: 0.85
0.13
1.2
Interest Coverage 27.35
BIIB's Interest Coverage is ranked lower than
80% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BIIB: 27.35 )
Ranked among companies with meaningful Interest Coverage only.
BIIB' s Interest Coverage Range Over the Past 10 Years
Min: 21.56  Med: 43.53 Max: 132.77
Current: 27.35
21.56
132.77
Piotroski F-Score: 7
Altman Z-Score: 5.87
Beneish M-Score: -2.75
WACC vs ROIC
13.75%
22.22%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 10/10

vs
industry
vs
history
Operating Margin % 44.06
BIIB's Operating Margin % is ranked higher than
96% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. BIIB: 44.06 )
Ranked among companies with meaningful Operating Margin % only.
BIIB' s Operating Margin % Range Over the Past 10 Years
Min: 28.07  Med: 35.59 Max: 49.38
Current: 44.06
28.07
49.38
Net Margin % 24.08
BIIB's Net Margin % is ranked higher than
91% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. BIIB: 24.08 )
Ranked among companies with meaningful Net Margin % only.
BIIB' s Net Margin % Range Over the Past 10 Years
Min: 19.11  Med: 24.74 Max: 32.95
Current: 24.08
19.11
32.95
ROE % 24.30
BIIB's ROE % is ranked higher than
94% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. BIIB: 24.30 )
Ranked among companies with meaningful ROE % only.
BIIB' s ROE % Range Over the Past 10 Years
Min: 13.81  Med: 20.75 Max: 35.15
Current: 24.3
13.81
35.15
ROA % 13.03
BIIB's ROA % is ranked higher than
93% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. BIIB: 13.03 )
Ranked among companies with meaningful ROA % only.
BIIB' s ROA % Range Over the Past 10 Years
Min: 9.16  Med: 14.4 Max: 22.42
Current: 13.03
9.16
22.42
ROC (Joel Greenblatt) % 140.08
BIIB's ROC (Joel Greenblatt) % is ranked higher than
96% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. BIIB: 140.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BIIB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 67.06  Med: 124.23 Max: 214.48
Current: 140.08
67.06
214.48
3-Year Revenue Growth Rate 12.10
BIIB's 3-Year Revenue Growth Rate is ranked higher than
68% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. BIIB: 12.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BIIB' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -19.4  Med: 21.8 Max: 106
Current: 12.1
-19.4
106
3-Year EBITDA Growth Rate 15.50
BIIB's 3-Year EBITDA Growth Rate is ranked higher than
64% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. BIIB: 15.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BIIB' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 26.2 Max: 161.5
Current: 15.5
0
161.5
3-Year EPS without NRI Growth Rate -1.20
BIIB's 3-Year EPS without NRI Growth Rate is ranked lower than
57% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. BIIB: -1.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BIIB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 25.6 Max: 205.2
Current: -1.2
0
205.2
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BIIB's 30-Y Financials

Financials (Next Earnings Date: 2019-01-26 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2017

BIIB Guru Trades in Q4 2017

Leucadia National 1,537 sh (New)
Richard Pzena 931 sh (New)
Paul Tudor Jones 3,354 sh (New)
Caxton Associates 2,866 sh (New)
Ronald Muhlenkamp 24,682 sh (+0.55%)
Ron Baron 14,868 sh (+14.80%)
Joel Greenblatt 87,874 sh (+39.40%)
Richard Snow 211,462 sh (+0.48%)
John Buckingham 17,300 sh (+1.33%)
Jeff Auxier 28,155 sh (+0.04%)
Stanley Druckenmiller 109,400 sh (+127.92%)
Pioneer Investments 245,830 sh (+426.52%)
David Dreman 3,705 sh (unchged)
Murray Stahl 4,645 sh (unchged)
David Carlson 95,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 117,233 sh (unchged)
Jim Simons Sold Out
Ray Dalio Sold Out
Vanguard Health Care Fund 3,636,003 sh (-2.06%)
Ken Fisher 99,280 sh (-7.96%)
HOTCHKIS & WILEY 271,672 sh (-1.13%)
PRIMECAP Management 15,109,231 sh (-0.68%)
Jeremy Grantham 1,300 sh (-12.16%)
Steven Cohen 252,319 sh (-50.32%)
Mairs and Power 1,025 sh (-2.66%)
Mario Gabelli 1,650 sh (-1.49%)
Frank Sands 1,138,777 sh (-5.67%)
» More
Q1 2018

BIIB Guru Trades in Q1 2018

John Hussman 10,000 sh (New)
Jim Simons 627,661 sh (New)
Ray Dalio 77,197 sh (New)
Ken Fisher 123,409 sh (+24.30%)
Ronald Muhlenkamp 25,171 sh (+1.98%)
Ron Baron 17,193 sh (+15.64%)
Leucadia National 6,331 sh (+311.91%)
Joel Greenblatt 111,801 sh (+27.23%)
Richard Snow 237,890 sh (+12.50%)
Richard Pzena 1,747 sh (+87.65%)
John Buckingham 17,516 sh (+1.25%)
Jeremy Grantham 30,200 sh (+2223.08%)
Jeff Auxier 28,225 sh (+0.25%)
Steven Cohen 444,615 sh (+76.21%)
Paul Tudor Jones 5,638 sh (+68.10%)
David Dreman 3,705 sh (unchged)
David Carlson 95,000 sh (unchged)
Mairs and Power 1,025 sh (unchged)
Stanley Druckenmiller Sold Out
Mario Gabelli Sold Out
Frank Sands Sold Out
Vanguard Health Care Fund 3,592,903 sh (-1.19%)
Murray Stahl 4,575 sh (-1.51%)
HOTCHKIS & WILEY 267,672 sh (-1.47%)
PRIMECAP Management 14,953,231 sh (-1.03%)
Caxton Associates 2,671 sh (-6.80%)
Pioneer Investments 191,653 sh (-22.04%)
Eaton Vance Worldwide Health Sciences Fund 109,135 sh (-6.91%)
» More
Q2 2018

BIIB Guru Trades in Q2 2018

Ken Fisher 128,113 sh (+3.81%)
Leucadia National 12,075 sh (+90.73%)
Richard Pzena 1,790 sh (+2.46%)
Paul Tudor Jones 7,591 sh (+34.64%)
Pioneer Investments 201,519 sh (+5.15%)
Vanguard Health Care Fund 3,592,903 sh (unchged)
Ronald Muhlenkamp 25,171 sh (unchged)
Murray Stahl 4,575 sh (unchged)
David Carlson 95,000 sh (unchged)
Mairs and Power 1,025 sh (unchged)
Caxton Associates Sold Out
Ron Baron 10,085 sh (-41.34%)
Joel Greenblatt 85,107 sh (-23.88%)
Richard Snow 232,465 sh (-2.28%)
HOTCHKIS & WILEY 263,072 sh (-1.72%)
John Buckingham 17,456 sh (-0.34%)
PRIMECAP Management 14,921,936 sh (-0.21%)
John Hussman 5,000 sh (-50.00%)
Jeremy Grantham 8,010 sh (-73.48%)
Steven Cohen 146,000 sh (-67.16%)
Ray Dalio 22,819 sh (-70.44%)
Eaton Vance Worldwide Health Sciences Fund 63,797 sh (-41.54%)
Jeff Auxier 28,157 sh (-0.24%)
Jim Simons 321,500 sh (-48.78%)
» More
Q3 2018

BIIB Guru Trades in Q3 2018

Caxton Associates 5,867 sh (New)
Ken Fisher 130,181 sh (+1.61%)
Vanguard Health Care Fund 3,695,803 sh (+2.86%)
Richard Pzena 1,864 sh (+4.13%)
Jim Simons 846,075 sh (+163.16%)
Pioneer Investments 259,887 sh (+28.96%)
Ron Baron 10,175 sh (+0.89%)
Paul Tudor Jones 18,462 sh (+143.21%)
John Buckingham 17,777 sh (+1.84%)
Eaton Vance Worldwide Health Sciences Fund 63,797 sh (unchged)
David Carlson 95,000 sh (unchged)
Mairs and Power 1,025 sh (unchged)
Jeff Auxier 28,157 sh (unchged)
John Hussman Sold Out
PRIMECAP Management 14,873,796 sh (-0.32%)
Ronald Muhlenkamp 18,368 sh (-27.03%)
Richard Snow 177,099 sh (-23.82%)
Ray Dalio 20,432 sh (-10.46%)
Jeremy Grantham 5,600 sh (-30.09%)
HOTCHKIS & WILEY 253,172 sh (-3.76%)
Leucadia National 10,883 sh (-9.87%)
Murray Stahl 4,525 sh (-1.09%)
Joel Greenblatt 79,271 sh (-6.86%)
Steven Cohen 42,500 sh (-70.89%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:BIIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:ASX:CSL, LSE:SHP, NAS:CELG, NAS:VRTX, NAS:REGN, XKRX:068270, XKRX:207940, NAS:ALXN, NAS:GILD, HKSE:01177, XMCE:GRF.P, NAS:BMRN, XBRU:UCB, NAS:NKTR, OCSE:NZYM B, NAS:INCY, OCSE:GEN, NAS:BIVV, HKSE:02269, NAS:JUNO » details
Traded in other countries:BIIB.Austria, BIIB34.Brazil, IDP.Germany, BIIB.Mexico, BIIB.Switzerland, 0R1B.UK,
Headquarter Location:USA
Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurological, rare and autoimmune diseases.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen markets novel MS drugs Tysabri and Tecfidera independently. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.

Guru Investment Theses on Biogen Inc

Jeff Auxier Comments on Biogen - Nov 08, 2018

Biogen (NASDAQ:BIIB) is a market leader in the treatment of Multiple Sclerosis (MS) and Spinal Muscular Atrophy (SMA). In addition to their current treatments, Biogen has been heavily investing in research into Alzheimer’s drugs with two drugs, Aducanumab and E2609, currently in phase three trials.



According to analytics company GlobalData, the Alzheimer’s market is expected to grow to over $15 billion over the next decade. Biogen’s free cash flow for 2018 appears likely to exceed $4 billion. Zimmer Biomet Holdings (ZBH) 18.21% According to AARP, 10,000 baby boomers in the US turn 65 every single day. The demographics for Zimmer Biomet medical devices are improving. Zimmer Biomet is a leader in hip, shoulder, elbow and knee replacements as well as producing vital devices for heart and spinal surgery. Their free cash flow is over $1 billion annually. Merck & Co. (MRK) 17.80% Merck’s signature drug, Keytruda, is an immunotherapy that is currently approved to treat seven types of cancer. Keytruda works by blocking the PD-1 pathway that cancerous cells use to hide from the body’s T cells and then letting the patient’s own immune system destroy the cancer. Keytruda was recently approved in China for adults with unrespectable or metastatic melanoma. In addition to Keytruda, Merck has a strong pipeline that includes nineteen drugs in phase 3 trials and three drugs that have already passed phase 3 trials and are awaiting FDA approval.

From Jeff Auxier (Trades, Portfolio)'s third-quarter 2018 shareholder commentary.

Check out Jeff Auxier latest stock trades

Jeff Auxier Comments on Biogen - Aug 09, 2018

Biogen (NASDAQ:BIIB)



Biogen saw revenues increase by 9% to $3.4 billion. Revenue growth was driven by Spinal Muscular Atrophy drug Spinraza which saw a 108% increase in revenue. Spinraza is Biogen’s fastest growing drug which they hope will be able to offset the slowing Multiple Sclerosis product line. Biogen presented the detailed results for the phase II trials of their Alzheimer’s drug BAN2401 on July 25th. The results of the trial were positive with tested patients showing 30% less cognitive decline over 18 months than those who received the placebo, but the presentation garnered a mixed reception and caused Biogen’s stock to fall 9% in after-hours trading. Earlier in July, Biogen announced that the trials of the drug were looking very positive without giving any details, and this announcement may have caused many to anticipate that the results would be better than what was ultimately shown. Currently, Biogen’s stock is hurting from the results announcement, but their outlook is still positive in the long-run due to the strength of their pipeline. Another Alzheimer’s drug in Biogen’s pipeline, Aducanumab, just finished its enrollment for two phase III trials. This drug has been regarded as more promising than BAN2401, and if it is successful Biogen will have the only drug in a $12 billion market.

From Jeff Auxier (Trades, Portfolio)'s second quarter 2018 shareholder letter.

Check out Jeff Auxier latest stock trades

Jeff Auxier Comments on Biogen Inc. - May 07, 2018

Biogen Inc. (NASDAQ:BIIB)



On February 15, 2018, Merck discontinued a phase 3 trial of their BACE1 inhibitor, verubecestat, adding the potential Alzheimer’s treatment to a growing list of clinical failures from pharmaceutical companies. This shook investor confidence in Biogen who also has a BACE1 inhibitor currently in late-stage testing. However, Biogen’s leading Alzheimer’s candidate, aducanumab, takes a different approach than BACE1 inhibitors by reducing amyloid plaques in the brain vs. preventing the build-up. Biogen’s expansion by 510 patients in aducanumab’s late-stage study to confront the high variability in the primary endpoint has increased fears of another industry failure. With earnings over $22 this year the stock seems very cheap.



From Jeff Auxier (Trades, Portfolio)'s first-quarter 2018 shareholder letter.

Check out Jeff Auxier latest stock trades

Top Ranked Articles about Biogen Inc

Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data
International Prix Galien Recognizes SPINRAZA® as Best Biotechnology Product
Jeff Auxier Comments on Biogen Guru stock highlight
Biogen (NASDAQ:BIIB) is a market leader in the treatment of Multiple Sclerosis (MS) and Spinal Muscular Atrophy (SMA). In addition to their current treatments, Biogen has been heavily investing in research into Alzheimer’s drugs with two drugs, Aducanumab and E2609, currently in phase three trials.
Read more...
Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at Clinical Trials on Alzheimer’s Disease (CTAD)
Eisai and Biogen Announce Presentation of Additional Data From the Phase II Clinical Trial of BAN2401 in Early Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus
Biogen to Present Data from Alzheimer’s Disease Portfolio at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
IMRALDI™, Biogen’s Adalimumab Biosimilar Referencing Humira®, Is Launched in the European Union
Biogen Advances Research to Improve Outcomes for Patients With Multiple Sclerosis
New SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy

Ratios

vs
industry
vs
history
PE Ratio 20.62
BIIB's PE Ratio is ranked higher than
56% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 28.79 vs. BIIB: 20.62 )
Ranked among companies with meaningful PE Ratio only.
BIIB' s PE Ratio Range Over the Past 10 Years
Min: 10.8  Med: 20.18 Max: 40.88
Current: 20.62
10.8
40.88
Forward PE Ratio 12.22
BIIB's Forward PE Ratio is ranked higher than
75% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 28.41 vs. BIIB: 12.22 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 20.62
BIIB's PE Ratio without NRI is ranked higher than
56% of the 243 Companies
in the Global Biotechnology industry.

( Industry Median: 28.64 vs. BIIB: 20.62 )
Ranked among companies with meaningful PE Ratio without NRI only.
BIIB' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.8  Med: 20.18 Max: 40.88
Current: 20.62
10.8
40.88
Price-to-Owner-Earnings 13.88
BIIB's Price-to-Owner-Earnings is ranked higher than
75% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 34.35 vs. BIIB: 13.88 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BIIB' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.03  Med: 20.78 Max: 60.46
Current: 13.88
10.03
60.46
PB Ratio 4.69
BIIB's PB Ratio is ranked lower than
62% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. BIIB: 4.69 )
Ranked among companies with meaningful PB Ratio only.
BIIB' s PB Ratio Range Over the Past 10 Years
Min: 1.71  Med: 4.76 Max: 8.84
Current: 4.69
1.71
8.84
PS Ratio 5.03
BIIB's PS Ratio is ranked higher than
68% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BIIB: 5.03 )
Ranked among companies with meaningful PS Ratio only.
BIIB' s PS Ratio Range Over the Past 10 Years
Min: 2.58  Med: 5.2 Max: 10.99
Current: 5.03
2.58
10.99
Price-to-Free-Cash-Flow 13.67
BIIB's Price-to-Free-Cash-Flow is ranked higher than
78% of the 152 Companies
in the Global Biotechnology industry.

( Industry Median: 37.07 vs. BIIB: 13.67 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BIIB' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.25  Med: 17.21 Max: 34.04
Current: 13.67
9.25
34.04
Price-to-Operating-Cash-Flow 11.43
BIIB's Price-to-Operating-Cash-Flow is ranked higher than
81% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 29.99 vs. BIIB: 11.43 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BIIB' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.22  Med: 14.8 Max: 32.48
Current: 11.43
7.22
32.48
EV-to-EBIT 11.14
BIIB's EV-to-EBIT is ranked higher than
70% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. BIIB: 11.14 )
Ranked among companies with meaningful EV-to-EBIT only.
BIIB' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.5  Med: 13.3 Max: 30
Current: 11.14
7.5
30
EV-to-EBITDA 9.71
BIIB's EV-to-EBITDA is ranked higher than
69% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. BIIB: 9.71 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIIB' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.1  Med: 11.2 Max: 24.8
Current: 9.71
6.1
24.8
EV-to-Revenue 5.14
BIIB's EV-to-Revenue is ranked higher than
71% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. BIIB: 5.14 )
Ranked among companies with meaningful EV-to-Revenue only.
BIIB' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.5  Med: 5.2 Max: 10.9
Current: 5.14
2.5
10.9
PEG Ratio 0.77
BIIB's PEG Ratio is ranked higher than
72% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 2.02 vs. BIIB: 0.77 )
Ranked among companies with meaningful PEG Ratio only.
BIIB' s PEG Ratio Range Over the Past 10 Years
Min: 0.31  Med: 0.76 Max: 2.41
Current: 0.77
0.31
2.41
Shiller PE Ratio 30.03
BIIB's Shiller PE Ratio is ranked higher than
59% of the 86 Companies
in the Global Biotechnology industry.

( Industry Median: 42.91 vs. BIIB: 30.03 )
Ranked among companies with meaningful Shiller PE Ratio only.
BIIB' s Shiller PE Ratio Range Over the Past 10 Years
Min: 26.92  Med: 69.71 Max: 229.16
Current: 30.03
26.92
229.16
Current Ratio 2.75
BIIB's Current Ratio is ranked lower than
70% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. BIIB: 2.75 )
Ranked among companies with meaningful Current Ratio only.
BIIB' s Current Ratio Range Over the Past 10 Years
Min: 0.78  Med: 3.91 Max: 20.41
Current: 2.75
0.78
20.41
Quick Ratio 2.46
BIIB's Quick Ratio is ranked lower than
71% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. BIIB: 2.46 )
Ranked among companies with meaningful Quick Ratio only.
BIIB' s Quick Ratio Range Over the Past 10 Years
Min: 0.7  Med: 3.53 Max: 20.41
Current: 2.46
0.7
20.41
Days Inventory 184.75
BIIB's Days Inventory is ranked lower than
70% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. BIIB: 184.75 )
Ranked among companies with meaningful Days Inventory only.
BIIB' s Days Inventory Range Over the Past 10 Years
Min: 184.75  Med: 238.11 Max: 266.3
Current: 184.75
184.75
266.3
Days Sales Outstanding 69.66
BIIB's Days Sales Outstanding is ranked lower than
54% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. BIIB: 69.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIIB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.79  Med: 46.41 Max: 69.66
Current: 69.66
39.79
69.66
Days Payable 68.01
BIIB's Days Payable is ranked lower than
51% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. BIIB: 68.01 )
Ranked among companies with meaningful Days Payable only.
BIIB' s Days Payable Range Over the Past 10 Years
Min: 68.01  Med: 95.56 Max: 148.21
Current: 68.01
68.01
148.21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 3.40
BIIB's 3-Year Average Share Buyback Ratio is ranked higher than
99% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. BIIB: 3.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BIIB' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -92.1  Med: 3.4 Max: 33.7
Current: 3.4
-92.1
33.7

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 13.01
BIIB's Price-to-Tangible-Book is ranked lower than
89% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. BIIB: 13.01 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BIIB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.2  Med: 6.77 Max: 24.42
Current: 13.01
0.2
24.42
Price-to-Intrinsic-Value-Projected-FCF 1.32
BIIB's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
74% of the 193 Companies
in the Global Biotechnology industry.

( Industry Median: 3.12 vs. BIIB: 1.32 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BIIB' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.05  Med: 1.8 Max: 12.73
Current: 1.32
0.05
12.73
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.72
BIIB's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
82% of the 38 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. BIIB: 0.72 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
BIIB' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.46  Med: 0.92 Max: 7.58
Current: 0.72
0.46
7.58
Price-to-Median-PS-Value 0.97
BIIB's Price-to-Median-PS-Value is ranked lower than
59% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. BIIB: 0.97 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BIIB' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.16  Med: 1.29 Max: 13.69
Current: 0.97
0.16
13.69
Price-to-Peter-Lynch-Fair-Value 1.00
BIIB's Price-to-Peter-Lynch-Fair-Value is ranked higher than
67% of the 64 Companies
in the Global Biotechnology industry.

( Industry Median: 1.72 vs. BIIB: 1.00 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
BIIB' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.41  Med: 1.12 Max: 18.88
Current: 1
0.41
18.88
Price-to-Graham-Number 3.45
BIIB's Price-to-Graham-Number is ranked lower than
73% of the 200 Companies
in the Global Biotechnology industry.

( Industry Median: 2.27 vs. BIIB: 3.45 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BIIB' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.43  Med: 3.3 Max: 19.73
Current: 3.45
0.43
19.73
Earnings Yield (Greenblatt) % 9.00
BIIB's Earnings Yield (Greenblatt) % is ranked higher than
93% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. BIIB: 9.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BIIB' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.3  Med: 7.5 Max: 13.4
Current: 9
3.3
13.4
Forward Rate of Return (Yacktman) % 24.73
BIIB's Forward Rate of Return (Yacktman) % is ranked higher than
90% of the 135 Companies
in the Global Biotechnology industry.

( Industry Median: 11.41 vs. BIIB: 24.73 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BIIB' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 16.4  Med: 23 Max: 26.9
Current: 24.73
16.4
26.9

More Statistics

Revenue (TTM) (Mil) $13,233.60
EPS (TTM) $ 15.49
Beta1.99
Volatility33.03%
52-Week Range $249.17 - 388.67
Shares Outstanding (Mil)201.48

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 13,319 13,536 13,950 14,305
EBIT (Mil $) 6,453 6,814 7,217
EBITDA (Mil $) 7,182 7,402 7,764 7,978
EPS ($) 24.12 25.80 26.87 29.04
EPS without NRI ($) 24.12 25.80 26.87 29.04
EPS Growth Rate
(Future 3Y To 5Y Estimate)
7.10%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}